Cargando…

Applications and challenges of biomaterial mediated mRNA delivery

With the rapid development of gene therapy technology and the outbreak of coronavirus disease 2019 (COVID-19), messenger RNA (mRNA) therapeutics have attracted more and more attention, and the COVID-19 mRNA vaccine has been approved by the Food and Drug Administration (FDA) for emergency authorizati...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Huapan, Chen, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446159/
https://www.ncbi.nlm.nih.gov/pubmed/36071982
http://dx.doi.org/10.37349/etat.2022.00093
_version_ 1784783587366666240
author Fang, Huapan
Chen, Qian
author_facet Fang, Huapan
Chen, Qian
author_sort Fang, Huapan
collection PubMed
description With the rapid development of gene therapy technology and the outbreak of coronavirus disease 2019 (COVID-19), messenger RNA (mRNA) therapeutics have attracted more and more attention, and the COVID-19 mRNA vaccine has been approved by the Food and Drug Administration (FDA) for emergency authorization. To improve the delivery efficiency of mRNA in vitro and in vivo, researchers have developed a variety of mRNA carriers and explored different administration routes. This review will systematically introduce the types of mRNA vectors, routes of administration, storage methods, safety of mRNA therapeutics, and the type of diseases that mRNA drugs are applied for. Finally, some suggestions are supplied on the development direction of mRNA therapeutic agents in the future.
format Online
Article
Text
id pubmed-9446159
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Open Exploration
record_format MEDLINE/PubMed
spelling pubmed-94461592022-09-06 Applications and challenges of biomaterial mediated mRNA delivery Fang, Huapan Chen, Qian Explor Target Antitumor Ther Review With the rapid development of gene therapy technology and the outbreak of coronavirus disease 2019 (COVID-19), messenger RNA (mRNA) therapeutics have attracted more and more attention, and the COVID-19 mRNA vaccine has been approved by the Food and Drug Administration (FDA) for emergency authorization. To improve the delivery efficiency of mRNA in vitro and in vivo, researchers have developed a variety of mRNA carriers and explored different administration routes. This review will systematically introduce the types of mRNA vectors, routes of administration, storage methods, safety of mRNA therapeutics, and the type of diseases that mRNA drugs are applied for. Finally, some suggestions are supplied on the development direction of mRNA therapeutic agents in the future. Open Exploration 2022 2022-08-31 /pmc/articles/PMC9446159/ /pubmed/36071982 http://dx.doi.org/10.37349/etat.2022.00093 Text en © The Author(s) 2022. https://creativecommons.org/licenses/by/4.0/This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Fang, Huapan
Chen, Qian
Applications and challenges of biomaterial mediated mRNA delivery
title Applications and challenges of biomaterial mediated mRNA delivery
title_full Applications and challenges of biomaterial mediated mRNA delivery
title_fullStr Applications and challenges of biomaterial mediated mRNA delivery
title_full_unstemmed Applications and challenges of biomaterial mediated mRNA delivery
title_short Applications and challenges of biomaterial mediated mRNA delivery
title_sort applications and challenges of biomaterial mediated mrna delivery
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446159/
https://www.ncbi.nlm.nih.gov/pubmed/36071982
http://dx.doi.org/10.37349/etat.2022.00093
work_keys_str_mv AT fanghuapan applicationsandchallengesofbiomaterialmediatedmrnadelivery
AT chenqian applicationsandchallengesofbiomaterialmediatedmrnadelivery